Schrödinger

Schrödinger has introduced robust prediction of relative binding energies for protein–protein complex mutations using free energy perturbation calculations, replacing the previous focus on OPLS5 polarizability and metal treatment...

Schrödinger is a leading scientific software and biotechnology company that specializes in developing advanced computational tools...

Schrödinger's stock is skyrocketing in 2025 as the market favors smaller companies with a market value between $1 billion and $5 billion...

Schrödinger introduced a next-generation tool, FEP+ Residue Scan, offering a 15x speedup in protein engineering predictions, and announced the discovery of KAI-11101, a preclinical DLK inhibitor for neurodegenerative diseases...

Christine Maraccini has left Schrödinger as Director, Global Payroll in the United States to join Portland Trail Blazers @ the Rose Quarter as Payroll Manager...

Schrödinger is currently seeking a Director, GxP Quality Assurance and Compliance in the United States...

Schrödinger's Executive Director Zhe Nie announced the publication of a paper on a new low-dose DHODH inhibitor for malaria chemoprevention...

Schrödinger's Executive Director Zhe Nie announced a collaboration with Structure Therapeutics in the discovery of ACCG-2671, a lead oral small molecule amylin receptor agonist expected to enter Phase 1 clinical development by the end of 2025...